Diffuse large B cell lymphoma overview: Difference between revisions
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AS}} | {{CMG}}; {{AE}} {{AS}} | ||
==Overview== | ==Overview== | ||
'''Diffuse large B-cell lymphoma (DLBCL or DLBL)''' is a [[cancer]] of [[B cell]]s, a type of [[white blood cell]] responsible for producing [[antibody|antibodies]]. Diffuse large B cell lymphoma may be classified based on location into nodal and extranodal disease and based on [[molecular]], [[genetic]], and [[immunohistochemical]] features into more than 20 subgroups. Diffuse large B cell lymphoma may be classified into 2 subtypes based on [[gene expression]] profiles. The progression to diffuse large B cell lymphoma involves the [[microRNAs]] (miRNAs). On microscopic histopathological analysis, diffuse large B cell lymphoma can be divided into three variants: centroblastic, immunoblastic, and anaplastic. There are no established causes for diffuse large B cell lymphoma. Diffuse large B cell lymphoma is the most common type of [[non-Hodgkin lymphoma]] among adults,<ref name="Blood1997">{{cite journal |pmid=9166827 |year=1997 |title=A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project |journal=Blood |volume=89 |issue=11 |pages=3909–18 |url=http://www.bloodjournal.org/content/89/11/3909 }}</ref> with an annual [[Incidence (epidemiology)|incidence]] of 7–8 cases per 100,000 people per year.<ref name="Morton2006">{{cite journal |doi=10.1182/blood-2005-06-2508 |pmid=16150940 |pmc=1895348 |title=Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001 |journal=Blood |volume=107 |issue=1 |pages=265–76 |year=2006 |last1=Morton |first1=L. M. |last2=Wang |first2=S. S. |last3=Devesa |first3=S. S. |last4=Hartge |first4=P |last5=Weisenburger |first5=D. D. |last6=Linet |first6=M. S. }}</ref><ref name="Smith2011">{{cite journal |doi=10.1038/bjc.2011.450 |pmid=22045184 |pmc=3242607 |title=Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network |journal=British Journal of Cancer |volume=105 |issue=11 |pages=1684–92 |year=2011 |last1=Smith |first1=A |last2=Howell |first2=D |last3=Patmore |first3=R |last4=Jack |first4=A |last5=Roman |first5=E }}</ref>This cancer occurs primarily in older individuals, with a median age of diagnosis at approximately 70 years of age,<ref name="Smith2011" /> though it can also occur in children and young adults in rare cases.<ref name="Smith2010">{{cite journal |doi=10.1111/j.1365-2141.2009.08010.x |pmid=19958356 |pmc=3066245 |title=The Haematological Malignancy Research Network (HMRN): A new information strategy for population based epidemiology and health service research |journal=British Journal of Haematology |volume=148 |issue=5 |pages=739–53 |year=2010 |last1=Smith |first1=Alexandra |last2=Roman |first2=Eve |last3=Howell |first3=Debra |last4=Jones |first4=Richard |last5=Patmore |first5=Russell |last6=Jack |first6=Andrew |author7=Haematological Malignancy Research Network }}</ref>The most potent risk factor in the development of diffuse large B cell lymphoma is [[immunodeficiency]]. Diffuse large B cell lymphoma must be differentiated from other diseases such as [[follicular lymphoma]], [[Mucosa-Associated Lymphatic Tissue lymphoma]](MALT), [[small cell lymphocytic lymphoma]], and [[Mantle cell lymphoma]] (MCL). The prognosis of diffuse large B cell lymphoma depends on the stage of the disease. Diffuse large B cell lymphoma is associated with a 5 year survival rate ranging from 70% to more than 90% among children. According to the Lugano classification, there are four stages of diffuse large B cell lymphoma based on the number of nodes involved and extranodal status. The most common symptoms of diffuse large B cell lymphoma include a rapidly enlarging, non-painful mass that may be located in neck, groin or abdomen. The less common symptoms of diffuse large B cell lymphoma include fever, weight loss and drenching night sweats. Common physical examination findings of diffuse large B cell lymphoma include a non tender mass which can arise in virtually any part of the body.Laboratory tests of diffuse large B cell lymphoma include [[cytology]], [[genetic testing]], histologic confirmation, and [[immunophenotyping]]. [[CT]] scan and [[MRI]] may be helpful in the diagnosis of diffuse large B cell lymphoma. Lymph node or extranodal tissue [[biopsy]] is diagnostic of large B cell lymphoma. Other diagnostic studies for diffuse large B cell lymphoma include laparoscopy, laparotomy, PET scan, and bone marrow aspiration and biopsy. The optimal therapy for diffuse large B cell lymphoma depends on the stage at diagnosis. The predominant therapy for diffuse large B cell lymphoma is [[chemotherapy]]. Adjunctive [[radiotherapy]] may be required. Active areas of research include genetic studies to assess the genetic role in diffuse large B cell lymphoma and novel therapeutic regimens that evaluate the efficacy and safety of novel regimens in in newly diagnosed diffuse large B cell lymphoma. | '''Diffuse large B-cell lymphoma (DLBCL or DLBL)''' is a [[cancer]] of [[B cell]]s, a type of [[white blood cell]] responsible for producing [[antibody|antibodies]]. Diffuse large B cell lymphoma may be classified based on location into nodal and extranodal disease and based on [[molecular]], [[genetic]], and [[immunohistochemical]] features into more than 20 subgroups. Diffuse large B cell lymphoma may be classified into 2 subtypes based on [[gene expression]] profiles. The progression to diffuse large B cell lymphoma involves the [[microRNAs]] (miRNAs). On microscopic histopathological analysis, diffuse large B cell lymphoma can be divided into three variants: centroblastic, immunoblastic, and anaplastic. There are no established causes for diffuse large B cell lymphoma. Diffuse large B cell lymphoma is the most common type of [[non-Hodgkin lymphoma]] among adults,<ref name="Blood1997">{{cite journal |pmid=9166827 |year=1997 |title=A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project |journal=Blood |volume=89 |issue=11 |pages=3909–18 |url=http://www.bloodjournal.org/content/89/11/3909 }}</ref> with an annual [[Incidence (epidemiology)|incidence]] of 7–8 cases per 100,000 people per year.<ref name="Morton2006">{{cite journal |doi=10.1182/blood-2005-06-2508 |pmid=16150940 |pmc=1895348 |title=Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001 |journal=Blood |volume=107 |issue=1 |pages=265–76 |year=2006 |last1=Morton |first1=L. M. |last2=Wang |first2=S. S. |last3=Devesa |first3=S. S. |last4=Hartge |first4=P |last5=Weisenburger |first5=D. D. |last6=Linet |first6=M. S. }}</ref><ref name="Smith2011">{{cite journal |doi=10.1038/bjc.2011.450 |pmid=22045184 |pmc=3242607 |title=Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network |journal=British Journal of Cancer |volume=105 |issue=11 |pages=1684–92 |year=2011 |last1=Smith |first1=A |last2=Howell |first2=D |last3=Patmore |first3=R |last4=Jack |first4=A |last5=Roman |first5=E }}</ref>This cancer occurs primarily in older individuals, with a median age of diagnosis at approximately 70 years of age,<ref name="Smith2011" /> though it can also occur in children and young adults in rare cases.<ref name="Smith2010">{{cite journal |doi=10.1111/j.1365-2141.2009.08010.x |pmid=19958356 |pmc=3066245 |title=The Haematological Malignancy Research Network (HMRN): A new information strategy for population based epidemiology and health service research |journal=British Journal of Haematology |volume=148 |issue=5 |pages=739–53 |year=2010 |last1=Smith |first1=Alexandra |last2=Roman |first2=Eve |last3=Howell |first3=Debra |last4=Jones |first4=Richard |last5=Patmore |first5=Russell |last6=Jack |first6=Andrew |author7=Haematological Malignancy Research Network }}</ref>The most potent risk factor in the development of diffuse large B cell lymphoma is [[immunodeficiency]]. Diffuse large B cell lymphoma must be differentiated from other diseases such as [[follicular lymphoma]], [[Mucosa-Associated Lymphatic Tissue lymphoma]](MALT), [[small cell lymphocytic lymphoma]], and [[Mantle cell lymphoma]] (MCL). The prognosis of diffuse large B cell lymphoma depends on the stage of the disease. Diffuse large B cell lymphoma is associated with a 5 year survival rate ranging from 70% to more than 90% among children. According to the Lugano classification, there are four stages of diffuse large B cell lymphoma based on the number of nodes involved and extranodal status. The most common symptoms of diffuse large B cell lymphoma include a rapidly enlarging, non-painful mass that may be located in neck, groin or abdomen. The less common symptoms of diffuse large B cell lymphoma include fever, weight loss and drenching night sweats. Common physical examination findings of diffuse large B cell lymphoma include a non tender mass which can arise in virtually any part of the body.Laboratory tests of diffuse large B cell lymphoma include [[cytology]], [[genetic testing]], histologic confirmation, and [[immunophenotyping]]. [[CT]] scan and [[MRI]] may be helpful in the diagnosis of diffuse large B cell lymphoma. Lymph node or extranodal tissue [[biopsy]] is diagnostic of large B cell lymphoma. Other diagnostic studies for diffuse large B cell lymphoma include [[laparoscopy]], [[laparotomy]], [[PET scan]], and [[bone marrow aspiration]] and biopsy. The optimal therapy for diffuse large B cell lymphoma depends on the stage at diagnosis. The predominant therapy for diffuse large B cell lymphoma is [[chemotherapy]]. Adjunctive [[radiotherapy]] may be required. Active areas of research include genetic studies to assess the genetic role in diffuse large B cell lymphoma and novel therapeutic regimens that evaluate the efficacy and safety of novel regimens in in newly diagnosed diffuse large B cell lymphoma. | ||
==Classification== | ==Classification== | ||
Diffuse large B cell lymphoma may be classified based on location into nodal and extranodal disease and based on [[molecular]], [[genetic]], and [[immunohistochemical]] features into more than 20 subgroups. | Diffuse large B cell lymphoma may be classified based on location into nodal and extranodal disease and based on [[molecular]], [[genetic]], and [[immunohistochemical]] features into more than 20 subgroups. | ||
| Line 41: | Line 41: | ||
Lymph node or extranodal tissue [[biopsy]] is diagnostic of large B cell lymphoma. | Lymph node or extranodal tissue [[biopsy]] is diagnostic of large B cell lymphoma. | ||
===Other Diagnostic Studies=== | ===Other Diagnostic Studies=== | ||
Other diagnostic studies for diffuse large B cell lymphoma include laparoscopy, laparotomy, PET scan, and bone marrow aspiration and biopsy. | Other diagnostic studies for diffuse large B cell lymphoma include [[laparoscopy]], [[laparotomy]], [[PET scan]], and [[bone marrow aspiration]] and [[biopsy]]. | ||
==Treatment== | ==Treatment== | ||
===Medical therapy=== | ===Medical therapy=== | ||
Revision as of 14:02, 31 August 2015
|
Diffuse large B cell lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Diffuse large B cell lymphoma overview On the Web |
|
American Roentgen Ray Society Images of Diffuse large B cell lymphoma overview |
|
Directions to Hospitals Treating Diffuse large B cell lymphoma |
|
Risk calculators and risk factors for Diffuse large B cell lymphoma overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]
Overview
Diffuse large B-cell lymphoma (DLBCL or DLBL) is a cancer of B cells, a type of white blood cell responsible for producing antibodies. Diffuse large B cell lymphoma may be classified based on location into nodal and extranodal disease and based on molecular, genetic, and immunohistochemical features into more than 20 subgroups. Diffuse large B cell lymphoma may be classified into 2 subtypes based on gene expression profiles. The progression to diffuse large B cell lymphoma involves the microRNAs (miRNAs). On microscopic histopathological analysis, diffuse large B cell lymphoma can be divided into three variants: centroblastic, immunoblastic, and anaplastic. There are no established causes for diffuse large B cell lymphoma. Diffuse large B cell lymphoma is the most common type of non-Hodgkin lymphoma among adults,[1] with an annual incidence of 7–8 cases per 100,000 people per year.[2][3]This cancer occurs primarily in older individuals, with a median age of diagnosis at approximately 70 years of age,[3] though it can also occur in children and young adults in rare cases.[4]The most potent risk factor in the development of diffuse large B cell lymphoma is immunodeficiency. Diffuse large B cell lymphoma must be differentiated from other diseases such as follicular lymphoma, Mucosa-Associated Lymphatic Tissue lymphoma(MALT), small cell lymphocytic lymphoma, and Mantle cell lymphoma (MCL). The prognosis of diffuse large B cell lymphoma depends on the stage of the disease. Diffuse large B cell lymphoma is associated with a 5 year survival rate ranging from 70% to more than 90% among children. According to the Lugano classification, there are four stages of diffuse large B cell lymphoma based on the number of nodes involved and extranodal status. The most common symptoms of diffuse large B cell lymphoma include a rapidly enlarging, non-painful mass that may be located in neck, groin or abdomen. The less common symptoms of diffuse large B cell lymphoma include fever, weight loss and drenching night sweats. Common physical examination findings of diffuse large B cell lymphoma include a non tender mass which can arise in virtually any part of the body.Laboratory tests of diffuse large B cell lymphoma include cytology, genetic testing, histologic confirmation, and immunophenotyping. CT scan and MRI may be helpful in the diagnosis of diffuse large B cell lymphoma. Lymph node or extranodal tissue biopsy is diagnostic of large B cell lymphoma. Other diagnostic studies for diffuse large B cell lymphoma include laparoscopy, laparotomy, PET scan, and bone marrow aspiration and biopsy. The optimal therapy for diffuse large B cell lymphoma depends on the stage at diagnosis. The predominant therapy for diffuse large B cell lymphoma is chemotherapy. Adjunctive radiotherapy may be required. Active areas of research include genetic studies to assess the genetic role in diffuse large B cell lymphoma and novel therapeutic regimens that evaluate the efficacy and safety of novel regimens in in newly diagnosed diffuse large B cell lymphoma.
Classification
Diffuse large B cell lymphoma may be classified based on location into nodal and extranodal disease and based on molecular, genetic, and immunohistochemical features into more than 20 subgroups.
Pathophysiology
Diffuse large B cell lymphoma may be classified into 2 subtypes based on gene expression profiles. The progression to diffuse large B cell lymphoma involves the microRNAs (miRNAs). On microscopic histopathological analysis, diffuse large B cell lymphoma can be divided into three variants: centroblastic, immunoblastic, and anaplastic.
Causes
There are no established causes for diffuse large B cell lymphoma.
Differential diagnosis
Diffuse large B cell lymphoma must be differentiated from other diseases such as follicular lymphoma, Mucosa-Associated Lymphatic Tissue lymphoma(MALT), small cell lymphocytic lymphoma, and mantle cell lymphoma (MCL).
Epidemiology and demographics
Diffuse large B cell lymphoma is the most common type of non-Hodgkin lymphoma among adults,[1] with an annual incidence of 7–8 cases per 100,000 people per year[2][3]. This cancer occurs primarily in older individuals, with a median age of diagnosis at approximately 70 years of age,[3] though it can also occur in children and young adults in rare cases[4].
Risk factors
The most potent risk factor in the development of diffuse large B cell lymphoma is immunodeficiency.
Screening
Screening for diffuse large B cell lymphoma is not recommended.
Prognosis
The prognosis of diffuse large B cell lymphoma depends on the stage of the disease. Diffuse large B cell lymphoma is associated with a 5 year survival rate ranging from 70% to more than 90% among children.
Diagnosis
Staging
According to the Lugano classification, there are four stages of diffuse large B cell lymphoma based on the number of nodes involved and extranodal status.
History and symptoms
The most common symptoms of diffuse large B cell lymphoma include a rapidly enlarging, non-painful mass that may be located in neck, groin or abdomen. The less common symptoms of diffuse large B cell lymphoma include fever, weight loss and drenching night sweats.
Physical examination
Common physical examination findings of diffuse large B cell lymphoma include a non tender mass which can arise in virtually any part of the body.
Laboratory Findings
Laboratory tests of diffuse large B cell lymphoma include cytology, genetic testing, histologic confirmation, and immunophenotyping.
Electrocardiogram
There are no electrocardiogam findings associated with diffuse large B cell lymphoma.
Chest X ray
There are no chest X ray findings associated with diffuse large B cell lymphoma.
CT
CT scan may be helpful in the diagnosis of diffuse large B cell lymphoma.
MRI
MRI may be helpful in the diagnosis of diffuse large B cell lymphoma.
Biopsy
Lymph node or extranodal tissue biopsy is diagnostic of large B cell lymphoma.
Other Diagnostic Studies
Other diagnostic studies for diffuse large B cell lymphoma include laparoscopy, laparotomy, PET scan, and bone marrow aspiration and biopsy.
Treatment
Medical therapy
The optimal therapy for diffuse large B cell lymphoma depends on the stage at diagnosis. The predominant therapy for diffuse large B cell lymphoma is chemotherapy. Adjunctive radiotherapy may be required.
Surgery
Surgical intervention is not recommended for the management of diffuse large B cell lymphoma.
Future or Investigational therapies
Active areas of research include genetic studies to assess the genetic role in diffuse large B cell lymphoma and novel therapeutic regimens that evaluate the efficacy and safety of novel regimens in in newly diagnosed diffuse large B cell lymphoma.
References
- ↑ 1.0 1.1 "A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project". Blood. 89 (11): 3909–18. 1997. PMID 9166827.
- ↑ 2.0 2.1 Morton, L. M.; Wang, S. S.; Devesa, S. S.; Hartge, P; Weisenburger, D. D.; Linet, M. S. (2006). "Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001". Blood. 107 (1): 265–76. doi:10.1182/blood-2005-06-2508. PMC 1895348. PMID 16150940.
- ↑ 3.0 3.1 3.2 3.3 Smith, A; Howell, D; Patmore, R; Jack, A; Roman, E (2011). "Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network". British Journal of Cancer. 105 (11): 1684–92. doi:10.1038/bjc.2011.450. PMC 3242607. PMID 22045184.
- ↑ 4.0 4.1 Smith, Alexandra; Roman, Eve; Howell, Debra; Jones, Richard; Patmore, Russell; Jack, Andrew; Haematological Malignancy Research Network (2010). "The Haematological Malignancy Research Network (HMRN): A new information strategy for population based epidemiology and health service research". British Journal of Haematology. 148 (5): 739–53. doi:10.1111/j.1365-2141.2009.08010.x. PMC 3066245. PMID 19958356.